ClinicalTrials.gg
RecruitingNCT03708900Updated Mar 27, 2026

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

A Phase 2 interventional study of LCI699 in Cushing Syndrome, sponsored by RECORDATI GROUP. Recruiting at 15 sites in 7 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by RECORDATI GROUP · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 58 studies in Cushing Syndrome with a site in United States — 14 open to participants now, 17 under way, none of them phase 3. Cushing Syndrome · United States.

Planned enrollment
29th of 34
12 · median 35
Started
2021
the only one that year
Phase 2
17 of 58
7 open now
Primary completion
2027-07
later than 4 of 16 live
Registered
38th of 58
by date
Lead sponsor
4 of 58
RECORDATI GROUP

Among the 58 studies in Cushing Syndrome with a site in United States, this one is the 29th largest by planned enrollment of the 34 interventional ones that give a count, is the only one that started in 2021, is one of 17 in phase 2, reaches primary completion later than 4 of the 16 other live ones, and was the 38th registered.

Cushing Syndrome

123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.

Browse Cushing Syndrome studies →

Open to participants now

14 of the 58 studies in Cushing Syndrome with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Cushing Syndrome with a site in United States, or all of them as a file.
02

Study summary

Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.

Read the detailed description

The period 1 study duration will be 12 weeks. The study will include a screening period of up to 4 weeks prior to Day 0 (baseline) (to allow for an adequate washout period from any medications that may modify cortisol levels). All subjects being treated with osilodrostat at 12 weeks and obtaining benefit from therapy, per investigator judgment, will be offered participation in an optional 9-month extension period, during which assessment of the PD activity and safety/tolerability of osilodrostat will be done. Patients who do not enter the optional extension period will have a safety follow up visit 4 weeks later.

03

Conditions studied

  • Cushing Syndrome

Keywords

  • Cushing's syndrome (CS)
  • LCI699
  • osilodrostat
  • Pituitary Gland
  • Adrenocorticotropic Hormone (ACTH)
  • Urinary Free Cortisol (UFC)
  • mean Urinary Free Cortisol (mUFC)
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female children and adolescents from 2 to \< 18 years of age with Cushing's syndrome of endogenous origin: Who have failed surgery (or) who are awaiting surgery (or) for whom surgery is not an immediate option. For patients who are awaiting surgery, the study treatment could be less than 12 weeks.
  2. Patients must weigh > 10 kg.
  3. The diagnosis of Cushing's syndrome must be confirmed by each of the following:

3a) The clinical criterion of decreasing growth percentiles with increasing weight (as evidenced by the presence of a contrast in height and SD scores, for example a SDS \< 0 and BMI SDS > 0, or a strong clinical suspicion of Cushing's syndrome, such as photographic evidence of a change in facial appearance); 3b) Abnormal low-dose (0.5 mg Q6h x 48 hours, or overnight 15mcg/kg [max 1 mg]) dexamethasone suppression test, defined as plasma cortisol levels > 1.8 mcg/dl, at time point 48 hours (0.5 mg Q6h x 48 hours) or 9 to 12 hours (overnight 15mcg/kg [max 1 mg]) after the first dose of dexamethasone; (OR) Midnight serum cortisol levels > , assessed while the patient is sleeping and after pre-cannulation (OR) two samples of late-night salivary cortisol greater than ULN for the assay. 3c)Two 24-hour urinary free cortisol values > 1.3 x ULN;

4. Able to swallow study drug tablets (not crushed or split) or the content of the capsules mixed with water.

5. Parents or legal guardians able to provide consent/assent.

Exclusion criteria

Exclusion Criteria

  1. Patients with macroadenoma complicated by compressive symptoms (requiring urgent surgical intervention) or at high risk for compressive symptoms due to mass effect of tumor (concern of corticotroph tumor progression).
  2. Insufficient from any other medication used to lower cortisol levels (5 half-lives of any drug).
  3. Use of other drugs at the time of enrollment, or within 30 days, or prior to completion of a wash-out duration that is at least 5 half- lives of the drug, at the time of enrollment, whichever is longer. Local regulations may require a longer wash-out period or specify other limitations for participation in an investigational trial, in which case they will be applicable as well.
  4. History of to drugs of the same or similar chemical classes as osilodrostat.
  5. History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  6. Patients with moderate to severe renal impairment (estimated \< 60 mL/min by the Creatinine-based "Bedside Schwartz" equation).
  7. Patients with serum and/or AST > 3 x , or total > 1.5 x ULN.
  8. History of thrombosis.
  9. Patients with risk factors for prolongation or Torsade de Pointes, including: 9a) patients with a baseline QTcF > 450 ms 9b) personal or family history of long QT syndrome 9c) concomitant medications known to prolong the QT interval 9d) patients with hypokalemia, hypocalcaemia, or hypomagnesaemia, if not corrected before pre-dose Day 0. In case of uncorrected hypokalemia (\<3.5 mEq/L), the screening period may be used to correct hypokalemia prior to starting study drug. Use of potassium supplements and/or mineralocorticoid antagonists is permitted during the study. 9e) Patients with a history of significant cardiovascular disease (based on the opinion of the investigator) such as: structural cardiovascular abnormalities, arrhythmia,
  10. Hypertensive patients with uncontrolled blood pressure defined as SBP > 150 and/or DBP > 100 or not optimally treated for hypertension as judged by the investigator.
  11. Patients who have undergone any major surgery within 1 month.
  12. Patients who have undergone trans-sphenoidal pituitary surgery within 6 weeks prior to screening are not eligible, unless they have clear evidence of persistent hypercortisolism or persistent biochemical changes consistent with Cushing's syndrome.
  13. Use of or anticipated use of systemic medications 1 month prior to screening.
  14. Uncontrolled hypothyroidism as evidenced by Free T4 \< 0.8 ng/dl.
  15. Uncontrolled hyper thyroidism.
  16. Diabetic patients with poorly controlled diabetes as evidenced by > 8.5 % or not optimally treated for diabetes mellitus as judged by the investigator.
  17. Positive pregnancy test in females of .
  18. Female patients of childbearing potential who do not agree to use highly effective methods .
  19. Pregnant or nursing (lactating) women.
  20. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. Any severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study treatment administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study.
  21. Use of concomitant prohibited medications
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    LCI699 (osilodrostat)

    Subjects with cushing's syndrome taking LCI699 (osilodrostat)

    Drug: LCI699

Interventions

  • DrugLCI699

    osilodrostat (LCI699) is in the form of tablets 1 milligram (mg), 5 mg, and 10mg or in form of capsules 0.1 mg, 0.2 mg, 0.5 mg, 1 mg or 5 mg, both the formulations for oral administration

    Also known as: osilodrostat

06

What researchers measure

Primary outcomes

  1. Core Study: Evaluate the pharmacokinetics (PK) of osilodrostat using Pharmacokinetic parameters of osilodrostat up to Week 12 in children and adolescents 2 to less than 18 years of age with Cushing's Syndrome

    evaluate the pharmacokinetics (PK) of osilodrostat in children and adolescents of 2 to less than 18 years of age with Cushing's Syndrome

    Time frame: up to Week 12

Secondary outcomes

  1. Core Study: Percentage of patients with normal mean urinary free cortisol (mUFC) at week 3, 6, 9 and week 12 (or end of treatment)

    The assessment in the core period will be done by taking the percentage of patients with normal mUFC at week 6 and week 12 (or end of treatment).

    Time frame: week 3, 6, 9 and week 12 (or end of treatment)

  2. Core Study: Change from baseline in mean urinary free cortisol (mUFC) during the core study period

    The assessment will be done by comparison of change from the baseline in mUFC during core study period on patients

    Time frame: week 3, 6, 9 and week 12 (or end of treatment)

  3. Extension: Efficacy of osilodrostat as measured by mUFC levels up to Month 12

    The assessment of efficacy of osilodrostat to be measured by change in baseline of mUFC levels up to 12 months on patients

    Time frame: up to month 12

  4. Extension: Efficacy of osilodrostat as measured by mUFC levels up to Month 12

    The assessment of efficacy of osilodrostat to be measured byproportion of patients with normal mUFC levels at each visit up to 12 months

    Time frame: up to month 12

  5. assessment of the pharmacodynamics, safety and tolerability of osilodrostat.

    Change from baseline in weight in core period

    Time frame: week 3, 6, 9 and week 12 (or end of treatment)

  6. assessment of the pharmacodynamics, safety and tolerability of osilodrostat up to 12 months

    Change from baseline in weight at each visit in extension period

    Time frame: up to 12 months

  7. assessment of the pharmacodynamics, safety and tolerability of osilodrostat.assessment of the pharmacodynamics, safety and tolerability of osilodrostat.

    Change from baseline in body mass index in core period

    Time frame: week 3, 6, 9 and week 12 (or end of treatment)

  8. assessment of the pharmacodynamics, safety and tolerability of osilodrostat.assessment of the pharmacodynamics, safety and tolerability of osilodrostat.

    Change from baseline in body mass index at each visit in extension period

    Time frame: up to 12 months

  9. assessment of the pharmacodynamics, safety and tolerability of osilodrostat.

    Change from baseline in height in core period

    Time frame: week 3, 6, 9 and week 12 (or end of treatment)

  10. assessment of the pharmacodynamics, safety and tolerability of osilodrostat.

    Change from baseline in height at each visit in extension period

    Time frame: up to 12 months

07

Study locations

4 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for Jul 2027, 74 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2018
First posted
Oct 17, 2018
StartActual
Apr 28, 2021
Primary completionEst.
Jul 21, 2027
CompletionEst.
Jul 21, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03708900
Lead sponsor
RECORDATI GROUP
Responsible party
Sponsor
First posted
Oct 17, 2018
Start date
Apr 28, 2021
Primary completion
Jul 21, 2027 (estimated)
Completion
Jul 21, 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Recordati
Contact
casi.m@recordati.it
+39 0248787456
Recordati
Contact
+4161 205 61 00
Recordati AG
study director · Recordati AG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osilodrostat

Start the discussion